Actualités Amarantus Bioscience Holdings Inc (CE) - AMBS | Actions OTCMarkets

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomar...

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in...

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for...

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of...

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of...

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF...

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Parkinson's LID

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID...

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating...

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive...

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

OMB APPROVAL OMB...

Amarantus Provides Comprehensive Corporate Update Recapitalization plan to use funding mechanisms created under the JOBS Act

Amarantus Provides Comprehensive Corporate Update - Recapitalization plan to use funding mechanisms created under the JOBS...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Amarantus Bioscience Holdings Inc (CE) (AMBS)

Outils de qualité professionnelle, pour des investisseurs individuels.

AMBS Actualités

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomar...

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Parkinson's LID

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating...

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Amarantus Provides Comprehensive Corporate Update Recapitalization plan to use funding mechanisms created under the JOBS Act

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Initial Statement of Beneficial Ownership (3)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Amarantus Bioscience Holdings Inc (CE) (AMBS) Actualités

Amarantus Bioscience Holdings Inc (CE) (AMBS)

Outils de qualité professionnelle, pour des investisseurs individuels.

AMBS Actualités

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomar...

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Parkinson's LID

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating...

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Amarantus Provides Comprehensive Corporate Update Recapitalization plan to use funding mechanisms created under the JOBS Act

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Initial Statement of Beneficial Ownership (3)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités